company background image
A352770 logo

Clinomics KOSDAQ:A352770 Stock Report

Last Price

₩515.00

Market Cap

₩19.8b

7D

-10.7%

1Y

-80.0%

Updated

24 Dec, 2024

Data

Company Financials

A352770 Stock Overview

A biotechnology company, provides genome-based cancer and disease diagnostic solutions. More details

A352770 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Clinomics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Clinomics
Historical stock prices
Current Share Price₩515.00
52 Week High₩3,080.00
52 Week Low₩449.00
Beta1.18
1 Month Change-16.94%
3 Month Change-30.12%
1 Year Change-80.04%
3 Year Change-93.80%
5 Year Changen/a
Change since IPO-95.93%

Recent News & Updates

Recent updates

Benign Growth For Clinomics Inc. (KOSDAQ:352770) Underpins Stock's 33% Plummet

Mar 15
Benign Growth For Clinomics Inc. (KOSDAQ:352770) Underpins Stock's 33% Plummet

Shareholder Returns

A352770KR BiotechsKR Market
7D-10.7%-4.0%-2.1%
1Y-80.0%16.1%-9.0%

Return vs Industry: A352770 underperformed the KR Biotechs industry which returned 16.1% over the past year.

Return vs Market: A352770 underperformed the KR Market which returned -9% over the past year.

Price Volatility

Is A352770's price volatile compared to industry and market?
A352770 volatility
A352770 Average Weekly Movement14.9%
Biotechs Industry Average Movement8.7%
Market Average Movement6.6%
10% most volatile stocks in KR Market12.7%
10% least volatile stocks in KR Market3.3%

Stable Share Price: A352770's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A352770's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
201173ByungChul Kimwww.clinomics.com

Clinomics Inc., a biotechnology company, provides genome-based cancer and disease diagnostic solutions. It provides TrioDx RT-PCR COVID-19 Test (FDA EUA), liquid biopsy and precision medicines, health care services, and big data solutions. The company’s liquid biopsy and precision medicines include CD-PRIME, a platform that offers automated protocols for the enrichment of circulating tumor cells (CTCs), cell free DNA, and EV (exosome) derived from cancer tissues; Cancer-PRIME, a cancer gene analysis service for analyzing results related to precision medicine information with bioinformatics and the detection of various gene mutations; and BioViewCCBS, a scanning platform that helps in capturing cells inside the sample in 3D and in finding and analyzing CTC inside the sample.

Clinomics Inc. Fundamentals Summary

How do Clinomics's earnings and revenue compare to its market cap?
A352770 fundamental statistics
Market cap₩19.80b
Earnings (TTM)-₩34.32b
Revenue (TTM)₩8.25b

2.4x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A352770 income statement (TTM)
Revenue₩8.25b
Cost of Revenue₩8.27b
Gross Profit-₩25.17m
Other Expenses₩34.29b
Earnings-₩34.32b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-892.63
Gross Margin-0.31%
Net Profit Margin-416.19%
Debt/Equity Ratio76.6%

How did A352770 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 18:08
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Clinomics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution